ATE281159T1 - Verwendung von aminosäure zur herstellung von arzneimitteln zur behandlung von insulinresistenz - Google Patents

Verwendung von aminosäure zur herstellung von arzneimitteln zur behandlung von insulinresistenz

Info

Publication number
ATE281159T1
ATE281159T1 AT00958726T AT00958726T ATE281159T1 AT E281159 T1 ATE281159 T1 AT E281159T1 AT 00958726 T AT00958726 T AT 00958726T AT 00958726 T AT00958726 T AT 00958726T AT E281159 T1 ATE281159 T1 AT E281159T1
Authority
AT
Austria
Prior art keywords
treatment
amino acid
insulin resistance
production
medicinal products
Prior art date
Application number
AT00958726T
Other languages
English (en)
Inventor
Gerard Ribes
Mohammed Taouis
Pierre Roger Petit
Christophe Broca
Yves Sauvaire
Bernard Pau
Original Assignee
Innodia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innodia filed Critical Innodia
Application granted granted Critical
Publication of ATE281159T1 publication Critical patent/ATE281159T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT00958726T 1999-08-27 2000-08-23 Verwendung von aminosäure zur herstellung von arzneimitteln zur behandlung von insulinresistenz ATE281159T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9910874A FR2797767B1 (fr) 1999-08-27 1999-08-27 Utilisation d'acides amines pour la fabrication de medicaments destines au traitement des insulino-resistances
PCT/FR2000/002361 WO2001015689A1 (fr) 1999-08-27 2000-08-23 Utilisation d'acides amines pour la fabrication de medicaments destines au traitement des insulino-resistances

Publications (1)

Publication Number Publication Date
ATE281159T1 true ATE281159T1 (de) 2004-11-15

Family

ID=9549397

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00958726T ATE281159T1 (de) 1999-08-27 2000-08-23 Verwendung von aminosäure zur herstellung von arzneimitteln zur behandlung von insulinresistenz

Country Status (14)

Country Link
US (2) US7402611B1 (de)
EP (2) EP1421937A1 (de)
JP (1) JP2003508435A (de)
CN (1) CN1208055C (de)
AT (1) ATE281159T1 (de)
AU (1) AU7015700A (de)
CA (1) CA2382835A1 (de)
DE (1) DE60015560T2 (de)
DK (1) DK1206257T3 (de)
ES (1) ES2231247T3 (de)
FR (1) FR2797767B1 (de)
PT (1) PT1206257E (de)
WO (1) WO2001015689A1 (de)
ZA (1) ZA200201619B (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7338675B2 (en) 2002-05-10 2008-03-04 Tsi Health Sciences, Inc. Fenugreek seed bio-active compositions and methods for extracting same
FR2847897B1 (fr) * 2002-12-02 2006-02-24 Centre Nat Rech Scient Procede de preparation de diasteroisomeres et d'enantiomeres de la 4-hydroxyisoleucine et de ses derives
WO2004083179A1 (ja) 2003-03-19 2004-09-30 Kyowa Hakko Kogyo Co., Ltd. 糖尿病治療剤
FR2856297B1 (fr) * 2003-06-18 2005-08-05 Caster Utilisation de (2s,3r,4s)-4-hydroxyisoleucine dans des compositions cosmetiques pour application topique
CA2543498A1 (en) * 2003-10-27 2005-05-06 Innodia Inc. Use of hydroxylated amino acids for treating diabetes
US7645466B2 (en) 2004-03-02 2010-01-12 Tsi Group Limited Methods for deriving, isolating, and/or extracting amino acid compositions from Fenugreek seed
WO2006017157A1 (en) * 2004-07-09 2006-02-16 Pure World Botanicals, Inc. Weight loss composition
BRPI0607140A2 (pt) * 2005-02-18 2009-08-11 Innodia Inc composto, uso do composto e/ou uso de um sal, lactona ou pró-medicamento farmaceuticamente aceitável do dito composto, composição farmacêutica, kit farmacêutico, método para estimular a captação de glicose pelas células musculares e/ou células de adipócito, método para estimular a secreção de insulina pelas células pancreáticas células-(beta) e método para o tratamento de um mamìfero que tem um distúrbio do metabolismo de carboidratos ou de lipìdios
CA2600954A1 (en) * 2005-03-22 2006-12-14 Innodia Inc. Compounds and compositions for use in the prevention and treatment of obesity and related syndromes
US20100048545A1 (en) * 2006-03-22 2010-02-25 Innodia Inc. Compounds and Compositions for Use in the Prevention and Treatment of Disorders of Fat Metabolism and Obesity
US20100124583A1 (en) * 2008-04-30 2010-05-20 Xyleco, Inc. Processing biomass
WO2008102671A1 (ja) 2007-02-22 2008-08-28 Ajinomoto Co., Inc. ４－ヒドロキシイソロイシンの精製方法
RU2636399C1 (ru) 2008-04-30 2017-11-23 Ксилеко, Инк. Переработка биомассы
CN108078973A (zh) * 2017-12-25 2018-05-29 郑州大学 4-羟基异亮氨酸的新用途
CN112089710B (zh) * 2020-08-07 2022-04-01 郑州大学 4-羟基异亮氨酸在制备抗肿瘤药物中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1011126A1 (ru) * 1981-07-14 1983-04-15 Всесоюзный научно-исследовательский и испытательный институт медицинской техники Средство дл лечени сахарного диабета
US5178867A (en) * 1991-08-19 1993-01-12 Alza Corporation Dosage form for delivering drug in short-time period
US5591709A (en) 1991-08-30 1997-01-07 Life Medical Sciences, Inc. Compositions and methods for treating wounds
FR2695317B1 (fr) * 1992-09-07 1995-03-10 Monal Lab Composition apte à stimuler la sécrétion d'insuline destinée au traitement du diabète non insulino-dépendant.
IL108583A (en) 1994-02-07 1997-06-10 Yissum Res Dev Co Galactomannan emulsions and comestible products containing the same
GB9517443D0 (en) * 1994-12-17 1995-10-25 Univ Nottingham Increasing creatine and glycogen concentration in muscle
FR2745718B1 (fr) * 1996-03-08 1998-05-07 Gestion Jouvenet Soc Civ De Composition antidiabetique a base de 4-hydroxyisoleucine
WO1998021592A1 (en) * 1996-11-13 1998-05-22 Receptron Corporation Assays for non-insulin dependent diabetes
ES2242995T3 (es) * 1997-01-15 2005-11-16 Telik, Inc. Moduladores de la actividad del receptor de la insulina.
CA2206157C (en) 1997-05-26 2000-06-13 Cheng, Peter Method of extraction of commercially valuable fractions of fenugreek

Also Published As

Publication number Publication date
CA2382835A1 (fr) 2001-03-08
CN1376062A (zh) 2002-10-23
ES2231247T3 (es) 2005-05-16
US7402611B1 (en) 2008-07-22
EP1206257A1 (de) 2002-05-22
WO2001015689A1 (fr) 2001-03-08
PT1206257E (pt) 2005-03-31
DK1206257T3 (da) 2005-03-14
EP1206257B1 (de) 2004-11-03
DE60015560T2 (de) 2005-12-15
JP2003508435A (ja) 2003-03-04
FR2797767B1 (fr) 2002-06-14
DE60015560D1 (de) 2004-12-09
FR2797767A1 (fr) 2001-03-02
US20080287344A1 (en) 2008-11-20
EP1421937A1 (de) 2004-05-26
AU7015700A (en) 2001-03-26
HK1052456A1 (en) 2003-09-19
ZA200201619B (en) 2003-07-30
CN1208055C (zh) 2005-06-29

Similar Documents

Publication Publication Date Title
DE60015560D1 (de) Verwendung von aminosäure zur herstellung von arzneimitteln zur behandlung von insulinresistenz
DE60103453D1 (de) Verwendung von albuminstabilisiertem Paclitaxel zur Herstellung eines Arzneimittels zum Behandeln von festen Tumoren und das so erhaltene Arzneimittel
DE69811371D1 (de) Verwendung von substanzen mit oxytocinwirkung zur herstellung von arzneimitteln zur wundheilung
ATE396198T1 (de) 17alpha-alkyl-17beta-oxy-estratriene und zwischenprodukte zu deren herstellung, verwendung der 17alpha-alkyl-17beta-oxy-estratriene zur herstellung von arzneimitteln sowie pharmazeutische präparate
MXPA03005340A (es) Nuevas composiciones de medicamentos a base de anticolinergicos y ciclesonida.
DE69534130D1 (de) Verbindungen zur behandlung von erkrankungen,die mit des vasculogenese und/oder angiogenese in verbunden stehen.
DE602004026701D1 (de) Implantierbares medizinprodukt zur selektiven modulation der abgabe von mitteln in situ
DE60136826D1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
DE69113386D1 (de) Herstellung von Medikamenten zur Behandlung von Asthma, unter Verwendung von (S)-Alpha-Fluoromethyl-Histidin und dessen Estern.
WO2003030927A3 (fr) Utilisation de peptides analogues de la thymuline (pat) pour la fabrication de medicaments contre la douleur
ATE269077T1 (de) Verwendung von tetrahydropyridinderivaten zur herstellung von arzneimitteln zur behandlung demyelinisierender erkrankungen
ATE368455T1 (de) Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz
DE69826023D1 (de) Verwendung von substanzen mit oxytocinwirkung zur herstellung eines arzneimittels zur behandlung affektiver schmerzsyndrome
DE59101776D1 (de) Verfahren zur Herstellung klein dimensionierter Formkörper mit hohem Etofibrat-Gehalt und kontrollierter Wirkstoff-Freisetzung, deren Verwendung und daraus bestehende oral verabreichbare Applikationsformen.
EP1114862A3 (de) Verwendung von Polypeptiden oder diese kodierende Nukleinsäuren zur Diagnose oder Behandlung von Hauterkrankungen sowie ihre Verwendung zur Identifizierung von pharmakologisch aktiven Substanzen
ATE246518T1 (de) Egr-1 zur herstellung eines medikamentes zur behandlung von wunden
ATE311866T1 (de) Verwendung von r-arylpropionsäuren zur herstellung von arzneimitteln zur behandlung von erkrankungen rheumatischer natur
DE69716223D1 (de) Vorrichtung zur Herstellung von medizinischen Pflastern zur perkutanen Verabreichung
ATE94764T1 (de) Nasal applizierbares arzneimittel, verfahren zu seiner herstellung und seine verwendung.
DE50100833D1 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
DE69719930D1 (de) Verfahren zur Herstellung von medizinischen Pflastern zur perkutanen Verabreichung, und Vorrichtung dafür
DE60006284D1 (de) Arzneimittel zur behandlung konvulsivischer zustände
DE60322871D1 (de) Thaltende zubereitungen
DE60336596D1 (de) Ortspezifische verabreichung von aktiven substanzen im darm
DE60122781D1 (de) Neue therapeutische verwendung eines derivates von thienylcyclohexylamine zur behandlung von schmerzen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1206257

Country of ref document: EP

REN Ceased due to non-payment of the annual fee